JP2009544721A - プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 - Google Patents

プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 Download PDF

Info

Publication number
JP2009544721A
JP2009544721A JP2009521914A JP2009521914A JP2009544721A JP 2009544721 A JP2009544721 A JP 2009544721A JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009544721 A JP2009544721 A JP 2009544721A
Authority
JP
Japan
Prior art keywords
chloro
phenyl
indol
pharmaceutically acceptable
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009521914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544721A5 (enExample
Inventor
チャウシア・ヤン
シュテファン・ライリング
サディーアス・アール・ニードゥザク
ローズ・エム・マシュー
シャロン・ジャクソン
キース・ジェイ・ハリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2009544721A publication Critical patent/JP2009544721A/ja
Publication of JP2009544721A5 publication Critical patent/JP2009544721A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009521914A 2006-07-25 2007-07-20 プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 Abandoned JP2009544721A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82030206P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82029906P 2006-07-25 2006-07-25
PCT/US2007/073945 WO2008014186A1 (en) 2006-07-25 2007-07-20 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2009544721A true JP2009544721A (ja) 2009-12-17
JP2009544721A5 JP2009544721A5 (enExample) 2010-09-02

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521914A Abandoned JP2009544721A (ja) 2006-07-25 2007-07-20 プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類

Country Status (25)

Country Link
US (1) US20090176804A1 (enExample)
EP (1) EP2066628B1 (enExample)
JP (1) JP2009544721A (enExample)
KR (1) KR20090039735A (enExample)
AR (1) AR062051A1 (enExample)
AT (1) ATE485270T1 (enExample)
AU (1) AU2007276885A1 (enExample)
BR (1) BRPI0714554A2 (enExample)
CA (1) CA2659055A1 (enExample)
CL (1) CL2007002163A1 (enExample)
CO (1) CO6190511A2 (enExample)
CR (1) CR10577A (enExample)
DE (1) DE602007010010D1 (enExample)
DK (1) DK2066628T3 (enExample)
EC (1) ECSP099087A (enExample)
GT (1) GT200900016A (enExample)
IL (1) IL196587A0 (enExample)
MA (1) MA30643B1 (enExample)
MX (1) MX2009000830A (enExample)
NO (1) NO20090862L (enExample)
PE (1) PE20080549A1 (enExample)
PT (1) PT2066628E (enExample)
TN (1) TNSN08515A1 (enExample)
TW (1) TW200821286A (enExample)
WO (1) WO2008014186A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
JP2021523135A (ja) * 2018-05-09 2021-09-02 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2346819T3 (da) * 2008-11-17 2013-05-13 Hoffmann La Roche Naphthyleddikesyre
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
TWI649321B (zh) 2014-03-17 2019-02-01 瑞士商愛杜西亞製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素d2受體調節劑之用途
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ, インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759073A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
JP2021523135A (ja) * 2018-05-09 2021-09-02 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体
JP7455762B2 (ja) 2018-05-09 2024-03-26 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体

Also Published As

Publication number Publication date
ATE485270T1 (de) 2010-11-15
DE602007010010D1 (de) 2010-12-02
CL2007002163A1 (es) 2008-02-08
MX2009000830A (es) 2009-02-03
DK2066628T3 (da) 2011-02-07
IL196587A0 (en) 2009-11-18
US20090176804A1 (en) 2009-07-09
CO6190511A2 (es) 2010-08-19
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
TW200821286A (en) 2008-05-16
EP2066628B1 (en) 2010-10-20
AU2007276885A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31
TNSN08515A1 (en) 2010-04-14
KR20090039735A (ko) 2009-04-22
PE20080549A1 (es) 2008-06-20
ECSP099087A (es) 2009-02-27
AR062051A1 (es) 2008-08-10
GT200900016A (es) 2010-10-13
MA30643B1 (fr) 2009-08-03
EP2066628A1 (en) 2009-06-10
CA2659055A1 (en) 2008-01-31
BRPI0714554A2 (pt) 2013-05-07
NO20090862L (no) 2009-02-24

Similar Documents

Publication Publication Date Title
JP2009544721A (ja) プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類
JP2009533473A (ja) プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−モノ置換アミノ−ピリミジン
US20070265278A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CN104284657A (zh) 用于抑制RORγ活性和治疗疾病的双环砜化合物
RU2493149C2 (ru) Замещенные метилфенилкетоны, пригодные для использования в качестве ингибиторов pde4
CN101287714B (zh) 前列腺素d2受体拮抗剂的磷酸二氢盐
JP6148400B2 (ja) フェノキシエチルジヒドロ−1h−イソキノリン化合物
WO2018222917A1 (en) Ire1 small molecule inhibitors
TW201443004A (zh) 苯氧基乙氧基化合物
RU2453540C2 (ru) 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
ES2352725T3 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
MX2012010038A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
US20100329998A1 (en) Novel heterocycles
US7816397B2 (en) Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes
CN101448789A (zh) 可溶性腺苷酸环化酶抑制剂
HK1110869A (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
HK1131975B (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100712

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20111129